Faeth Therapeutics, Inc.

NasdaqCM:FTH Stock Report

Market Cap: US$891.5m

Faeth Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:FTH Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
01 Jul 26BuyUS$326,127Brian StephensonIndividual13,634US$24.98
26 Jun 26BuyUS$401,269Brian StephensonIndividual15,641US$27.77
23 Jun 26BuyUS$405,921Brian StephensonIndividual17,413US$25.91
22 Jun 26BuyUS$55,447Anand ParikhIndividual2,806US$19.76
01 Jun 26SellUS$500,543James PeyerIndividual25,000US$21.14
01 Jun 26SellUS$500,543Cambrian BioPharma, Inc.Company25,000US$21.14
07 Apr 26BuyUS$1,294,872Millennium Management LLCCompany45,449US$35.55
07 Apr 26SellUS$659,414Millennium Management LLCCompany21,593US$34.80
01 Apr 26BuyUS$46,849Millennium Management LLCCompany1,531US$31.53
01 Apr 26SellUS$45,040Millennium Management LLCCompany1,474US$31.52
09 Dec 25SellUS$24,727Cambrian BioPharma, Inc.Company3,112US$7.95
09 Dec 25SellUS$51,399Cambrian BioPharma, Inc.Company6,217US$8.59
09 Dec 25SellUS$26,672Cambrian BioPharma, Inc.Company3,105US$8.59
05 Dec 25SellUS$232,690Cambrian BioPharma, Inc.Company21,295US$13.16

Insider Trading Volume

Insider Buying: FTH insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of FTH?
Owner TypeNumber of SharesOwnership Percentage
Private Companies130,1420.504%
Individual Insiders1,102,7934.27%
VC/PE Firms2,632,23210.2%
Hedge Funds3,464,14213.4%
General Public7,678,87929.7%
Institutions10,832,23741.9%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 1948.7%.

Top Shareholders

Top 25 shareholders own 67.6% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.2%
Khosla Ventures, LLC
2,632,232US$90.8m0%3.38%
7.82%
Montanova Capital, LLC
2,020,103US$69.7m5,750%1.68%
5.59%
Avoro Capital Advisors LLC
1,444,039US$49.8m0%0.48%
4.98%
Baker Bros. Advisors LP
1,286,411US$44.4m0%0.22%
4.03%
Balyasny Asset Management L.P.
1,042,198US$36.0m6,330%0.07%
3.98%
Cormorant Asset Management, LP
1,028,242US$35.5m236%1.95%
3.16%
Anand Parikh
817,699US$28.2m0%no data
2.79%
Vivo Capital, LLC
722,020US$24.9m0%2.26%
2.79%
RA Capital Management, L.P.
722,020US$24.9m0%0.22%
2.79%
Fairmount Funds Management LLC
722,020US$24.9m0%1.68%
2.79%
Logos Global Management, L.P.
722,020US$24.9m2,310%1.16%
2.44%
Caligan Partners, LP
629,467US$21.7m400%1.11%
2.36%
The B Group, Inc.
610,169US$21.1m0%12.05%
1.99%
Trails Edge Capital Partners, LP
515,335US$17.8m312%2.73%
1.91%
Franklin Templeton Inc.
494,516US$17.1m270%no data
1.4%
Octagon Capital Advisors LP
361,010US$12.5m0%1.33%
1.4%
ADAR1 Capital Management, LLC
361,010US$12.5m0%0.62%
0.86%
H&S Ventures LLC
222,081US$7.7m0%0.06%
0.8%
Marshall Wace LLP
206,508US$7.1m214%0.01%
0.7%
Boxer Capital Management, LLC
180,505US$6.2m0%0.53%
0.68%
Patient Square Capital, LP
175,050US$6.0m0%0.92%
0.56%
Alyeska Investment Group, L.P.
144,404US$5.0m0%0.01%
0.56%
Affinity Asset Advisors, LLC
144,404US$5.0m0%0.28%
0.52%
Boothbay Fund Management, LLC
133,643US$4.6m412%0.1%
0.5%
James Peyer
130,142US$4.5m0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/20 05:14
End of Day Share Price 2026/09/18 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Faeth Therapeutics, Inc. is covered by 19 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Zhiqiang ShuBerenberg
Suranjit MukherjeeBTIG